Supplemental Comment from Kenvue Brands LLC

Summary: Kenvue Brands LLC opposes the proposed labeling changes for over-the-counter acetaminophen products, arguing that the scientific evidence linking prenatal use to neurodevelopmental disorders is unreliable and methodologically flawed. The company contends that the requested warnings would be misleading, violate the First Amendment, and contradict the FDA's evidence-driven regulatory framework.